Pediatric Hematology Oncology Journal (Jan 2022)
Standardization of 13-color high-sensitivity measurable residual disease (MRD) assessment in B-cell lymphoblastic leukemia (B-ALL) treated with novel anti-CD19 immunotherapies
Abstract
No abstracts available.